Our data indicates that urinary NGAL and serum cystatin C individually can predict AKI and represent a novel biomarker for AKI and may enable clinicians to initiate timely intervention in management of AKI and may prevent long term poor prognostic situations in this particular group of patients. The gene discussed is CST3; the disease is acute kidney injury.